ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1426

Genotype and Transfusion Dependence Predicts Mortality in VEXAS Syndrome, a Newly Described Disease with Overlap Inflammatory and Hematologic Features
Abstract Number: 0368

Geographical Prevalence of Family History in Patients with Axial SpA and Its Association with HLA-B27: Data from the Worldwide ASAS-perSpA Study
Abstract Number: 1403

Giant Cell Arteritis Subtypes: Data from the ARTESER Registry
Abstract Number: 0502

Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Non-inflammatory Aortic Aneurysms
Abstract Number: 0694

Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Fiber Necroptosis and Muscle Inflammation and Ameliorates Muscle Weakness in Experimental Polymyositis
Abstract Number: 1735

Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation
Abstract Number: 1485

Glycosphingolipids: Potential Urine Biomarkers of Therapeutic Response in Lupus Nephritis
Abstract Number: 0742

Googling Rheumatic Diseases: Evaluating the Reliability of Information Found on the Internet
Abstract Number: 0682

Gout Management and Outcomes During the COVID-19 Pandemic in Late 2020-2021: A Cross-sectional Internet Survey
Abstract Number: 0680

Gout Stigma: Investigating the Existence of Gout Stigma and Its Impact on Patient Perceptions and Treatment Decisions
Abstract Number: 0968

Granzyme K+ CD8 T Cells Form the Core Population of Inflamed Human Tissue-associated CD8 T Cells
Abstract Number: 0173

Greater High-density Lipoprotein Levels over Time Are Linked to Lower Coronary Plaque Formation, Regression and Stabilization of High-risk Lesions in Rheumatoid Arthritis
Abstract Number: 1331

Guselkumab (TREMFYA®) Improves Anemia in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Randomized Controlled Clinical Trials
Abstract Number: 1329

Guselkumab (TREMFYA®) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study
Abstract Number: 1333

Guselkumab (TREMFYA®) Provides Consistent and Durable Pain Improvement in Patients with Active Psoriatic Arthritis: Results of 2 Phase 3, Randomized, Controlled Clinical Trials

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].